login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Preliminary results of CT angiography method for assessing haemodynamic significance of coronary lesions released


Wednesday, 11 Jul 2012 12:05
COR Analyzer
COR Analyzer


On 10 July, Rcadia Medical Imaging announced results of an initial study intended to demonstrate the feasibility of a proprietary technique that uses coronary CT angiography studies (cCTA) as a non-invasive alternative to assess the haemodynamic significance of coronary lesions.


“Determining the effect of an intermediate lesion on coronary blood flow is critical to making a treatment decision,” said Shai Levanon, president and CEO, Rcadia. “Currently, the standard technique for evaluating the haemodynamic significance of coronary lesions is by measuring fractional flow reserve (FFR) through invasive coronary catheterisation. Our initial study shows a good correlation to FFR, highlighting the potential of our technology to enhance the diagnostic utility of cCTA and reduce the number of invasive, costly diagnostic cardiac catheterisation produces.”

Levanon noted that Rcadia’s approach builds on its FDA cleared COR Analyzer System, which performs fully automatic detection of coronary stenosis from cCTA studies. “A capability for assessing haemodynamic significance has potential to provide a powerful complement to the COR Analyzer’s ability to identify significant stenosis in suspected patients with coronary artery disease.”


To assess the diagnostic performance of the method, Rcadia conducted a retrospective study based on 44 patients who underwent both cCTA and diagnostic coronary catheterisation with FFR measurements. Assessments using Rcadia’s proprietary technique were performed for 49 of 51 lesions with FFR measurements present in those studies. Two lesions were not evaluated due to poor image quality.


The Rcadia method correctly identified all 11 haemodynamically significant lesions (FFR <=0.8) and 33 of 38 haemodynamically insignificant lesions (FFR>0.8), yielding the sensitivity of 100% and specificity of 87%.




Add New Comment

Related Items


Most popular


European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices
Tuesday, 31 May 2016
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations ... European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices

Karl-Heinz Kuck steps down from the ESC and EHRA after fraud conviction
Wednesday, 08 Jun 2016
Karl-Heinz Kuck has withdrawn his candidacy for president-elect of the European Society of Cardiology (ESC) and also resigned from board of the European Heart Rhythm Association (EHRA). This follows ... Karl-Heinz Kuck steps down from the ESC and EHRA after fraud conviction

Biotronik’s scaffold is now approved for use in Europe
Wednesday, 15 Jun 2016
Biotronik’s bioresorbable magnesium scaffold—Magmaris—is now CE mark approved, meaning it is now one of three bioresorbable scaffolds available on the European market (alongside Abbott Vascular’s A... Biotronik’s scaffold is now approved for use in Europe

Features


TAVI durability: A rose by any other name is still a rose
Wednesday, 20 Jul 2016
The data that Dvir presented at EuroPCR, as reported by Cardiovascular News, indicate that there is a significant increase in valve degeneration between five and seven years after a transcatheter ... TAVI durability: A rose by any other name is still a rose

Exploring the borders of TAVI
Monday, 11 Jul 2016
The NOTION 2 trial, which recently enrolled a 64-year-old female with Society of Thoracic Surgeon (STS) score 1.2% as its first patient, is comparing the use of TAVI with the use of surgical aortic ... Exploring the borders of TAVI

Profiles


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions